M
Molly Hammond
Researcher at Baylor College of Medicine
Publications - 5
Citations - 130
Molly Hammond is an academic researcher from Baylor College of Medicine. The author has contributed to research in topics: Antigen & Adjuvant. The author has an hindex of 5, co-authored 5 publications receiving 106 citations. Previous affiliations of Molly Hammond include Boston Children's Hospital.
Papers
More filters
Journal ArticleDOI
Cysteine mutagenesis improves the production without abrogating antigenicity of a recombinant protein vaccine candidate for human chagas disease.
Christopher A. Seid,Kathryn M. Jones,Jeroen Pollet,Brian Keegan,Elissa M. Hudspeth,Molly Hammond,Junfei Wei,C. Patrick McAtee,Leroy Versteeg,Amanda M. Gutierrez,Zhuyun Liu,Bin Zhan,Jonathan L. Respress,Ulrich Strych,Maria Elena Bottazzi,Peter J. Hotez +15 more
TL;DR: Investigations are now underway to examine the efficacy of Tc24-C4 formulated with other adjuvants to reduce parasite burden and increase survival in pre-clinical studies.
Journal ArticleDOI
Expression, purification, immunogenicity, and protective efficacy of a recombinant Tc24 antigen as a vaccine against Trypanosoma cruzi infection in mice.
Viridiana Martinez-Campos,Pedro Martínez-Vega,Maria Jesus Ramirez-Sierra,Miguel Rosado-Vallado,Christopher A. Seid,Elissa M. Hudspeth,Junfei Wei,Zhuyun Liu,Cliff Kwityn,Molly Hammond,Jaime Ortega-López,Bin Zhan,Peter J. Hotez,Maria Elena Bottazzi,Eric Dumonteil +14 more
TL;DR: Full protective efficacy was shown regardless of whether the antigen was expressed in Escherichia coli or in yeast (Pichia pastoris), and such studies provide a basis for further evaluations of vaccines comprised of rTc24, together with alternative adjuvants and additional recombinant antigens.
Journal ArticleDOI
Optimization and revision of the production process of the Necator americanus glutathione S-transferase 1 (Na-GST-1), the lead hookworm vaccine recombinant protein candidate.
Elena Curti,Christopher A. Seid,Elissa M. Hudspeth,Wanderson C. Rezende,Jeroen Pollet,Cliff Kwityn,Molly Hammond,Risë K. Matsunami,David A. Engler,Peter J. Hotez,Maria Elena Bottazzi +10 more
TL;DR: Modifications to the fermentation and purification of the antigen expressed in P. pastoris allowed for a 2–3-fold improvement in the final yield of Na-GST-1 purified protein, which was sufficient for early pilot manufacturing and initial phase 1 clinical testing.
Journal ArticleDOI
Expression, purification, immunogenicity and protective efficacy of a recombinant nucleoside hydrolase from Leishmania donovani, a vaccine candidate for preventing cutaneous leishmaniasis
C. Patrick McAtee,Christopher A. Seid,Molly Hammond,Elissa M. Hudspeth,Brian Keegan,Zhuyun Liu,Junfei Wei,Bin Zhan,Raul Arjona-Sabido,Vladimir Cruz-Chan,Eric Dumonteil,Peter J. Hotez,Maria Elena Bottazzi,Maria Elena Bottazzi +13 more
TL;DR: Mice immunized with the LdNH36 antigen in combination with the GLA-SE adjuvant and challenged with Leishmania mexicana showed significant reductions in parasite burden, confirming the protective efficacy of this vaccine candidate.
Journal ArticleDOI
Expression and purification of an engineered, yeast-expressed Leishmania donovani nucleoside hydrolase with immunogenic properties.
Elissa M. Hudspeth,Qian Wang,Christopher A. Seid,Molly Hammond,Junfei Wei,Zhuyun Liu,Bin Zhan,Jeroen Pollet,Michael J. Heffernan,C. Patrick McAtee,David A. Engler,Risë K. Matsunami,Ulrich Strych,Oluwatoyin A. Asojo,Peter J. Hotez,Maria Elena Bottazzi +15 more
TL;DR: Results indicate that LdNH36-dg2 as expressed in and purified from P. pastoris is suitable for further scale-up, manufacturing, and testing in support of future first-in-humans phase 1 clinical trials.